American Well Corp (AMWL) Q3 2026 Earnings Call Highlights: Revenue Beat, Raised Guidance
American Well Corp (AMWL) reported Q3 2026 revenue of $49M, down 12.9% YoY. Subscription revenue fell 22.5% due to churn. Platform visits dropped 30.5% YoY. The VA letter of intent is non-binding, and the DHA contract conversion is pending. CEO Dr. Ido Schoenberg expressed optimism about negotiations and potential growth opportunities. The company expects Q4 adjusted EBITDA breakeven and raised guidance.
How this was made

The 30-second read
Why it matters
Near-term revenue visibility is constrained by non-binding LOI status and unknown VA start date, while longer-term upside depends on converting agreements and scaling outcomes-based clinical services.
Market read
Traders can reassess the balance between raised guidance and the timing risk of VA definitive contracting, which the company says could affect revenue recognition into 2027.
What to watch
Investors may underweight the operational momentum signals (3x engagement, 4.9/5 member ratings, virtual primary care visits up 40% YoY) that could improve utilization-driven revenue mix even if subscription growth remains choppy.
Background
The call centers on Amwell’s government payer contracting path (VA letter of intent to definitive contract, DHA conversion to longer-term direct agreement) and its subscription churn dynamics.
Ticker impact
Amwell reported Q3 2026 call highlights including revenue decline, churn details, and guidance raised, with VA LOI and DHA conversion timing uncertainty.
Likely mixed reaction, with upside from raised guidance tempered by uncertainty around VA definitive contract timing and ongoing churn.
The article provides both positive (raised guidance, engagement/outcomes metrics) and negative (12.9% revenue decline, subscription revenue down 22.5%, platform visits down 30.5%, VA LOI non-binding, start date unknown) items, making direction dependent on how investors weigh guidance versus timing risk.
Market effects
Reinforces that virtual care and payer-facing SaaS models are being judged on outcomes-based monetization and churn control, not just top-line growth.
No clear regional spillover beyond US healthcare IT and virtual care investor sentiment.
Limited, as the catalysts described are US government payer contracting and company-specific guidance.
Counterpoint
The raised guidance may be less durable if VA revenue is delayed into 2027 and subscription churn from de-emphasized businesses persists.
Key entities
- companyAmerican Well Corp
Subject of the earnings call highlights, including revenue/churn performance and guidance raised amid VA and DHA contracting uncertainty.
- executiveDr. Ido Schoenberg
CEO quoted on contract negotiations, engagement/outcomes metrics, and expectations for breakeven and growth drivers.
- executiveMark Hirschhorn
CFO/COO quoted on Q4 EBITDA breakeven expectations and churn/guidance framing.


